Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.53 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.44 |
| ▸ | WNT1 | P04628 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | PLD2 | O14939 | 3/20 | 0.38 |
| ▸ | PLD1 | Q13393 | 3/20 | 0.38 |
| ▸ | WDR5 | P61964 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10187944 | 1.00 | P2RX3 (0.53) | P2RX3P2RX2HDAC4HDAC6WNT1 | |
| SCHEMBL1714470 | 0.88 | P2RX3 (0.40) | P2RX3P2RX2P2RX7PLD2PLD1 | |
| SCHEMBL10187945 | 0.88 | P2RX3 (0.40) | P2RX3P2RX2P2RX7PLD2PLD1 | |
| SCHEMBL406064 | 0.84 | P2RX3 (0.53) | P2RX3P2RX2HDAC4HDAC6PLD2 | |
| SCHEMBL10187951 | 0.84 | P2RX3 (0.53) | P2RX3P2RX2HDAC4HDAC6PLD2 | |
| SCHEMBL405831 | 0.83 | P2RX3 (0.73) | P2RX3P2RX2HDAC4HDAC6WNT1 | |
| SCHEMBL10187943 | 0.83 | P2RX3 (0.73) | P2RX3P2RX2HDAC4HDAC6WNT1 | |
| SCHEMBL408703 | 0.82 | HPGD (0.42) | — | |
| SCHEMBL10243226 | 0.79 | P2RX3 (0.43) | P2RX3P2RX2HDAC4HDAC6PLD2 | |
| SCHEMBL10243053 | 0.79 | P2RX3 (0.43) | P2RX3P2RX2HDAC4HDAC6PLD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786110-B2 | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2010-08-31 | — | — | US | claimed |
| US-20120022067-A1 | THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | CHEN LI (CN) | 2012-01-26 | — | — | US | disclosed |
| EP-2091927-B1 | THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES | HOFFMANN LA ROCHE (CH) | 2011-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022067-A1 | THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX1 | P2RX3 1/4885P2RX2 2/4885HDAC4 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.